AstraZeneca Obesity Pipeline: What’s Coming

Introduction

AstraZeneca arrived late to the obesity drug race. While Novo Nordisk and Eli Lilly built their tirzepatide and semaglutide franchises through the early 2020s, AstraZeneca’s metabolic disease portfolio leaned on Farxiga (dapagliflozin), an SGLT2 inhibitor that competes in diabetes and cardiometabolic conditions but does little for weight.

The company’s obesity strategy now rests on three molecules: AZD5004 (also called ECC5004), an oral once-daily small-molecule GLP-1 licensed from Chinese biotech Eccogene in November 2023; AZD6234, an amylin analog in phase 2; and an early-stage GLP-1/glucagon dual agonist. None will hit the market before 2028 at earliest, and AstraZeneca’s CEO Pascal Soriot has acknowledged the company is playing catch-up.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Is AstraZeneca’s Main Obesity Drug Candidate?

AZD5004, also known as ECC5004, is an oral once-daily small-molecule GLP-1 receptor agonist. Unlike injectable peptides such as semaglutide and tirzepatide, AZD5004 is a non-peptide small molecule that can be absorbed through the gut without the bioavailability problems that limit oral peptide drugs.

Quick Answer: AstraZeneca licensed AZD5004 (ECC5004) from Eccogene in November 2023 for up to $1.825 billion in milestones

AstraZeneca licensed AZD5004 from Shanghai-based Eccogene in November 2023 in a deal worth up to $1.825 billion in upfront and milestone payments. Eccogene retains commercialization rights in China while AstraZeneca holds rest-of-world rights.

The molecule entered phase 2 trials in 2024 for obesity, type 2 diabetes, and cardiovascular disease. Initial readouts from a phase 1b study published in 2024 showed weight reduction of roughly 5.8% at 12 weeks compared with placebo, in line with early Lilly orforglipron data but well below what later orforglipron readouts showed at higher doses.

Full phase 2 data is expected in 2026, with phase 3 trials initiating in 2027 if results support advancement. The earliest realistic FDA approval timeline is 2029.

How Does AZD5004 Compare to Lilly’s Orforglipron?

Both are oral once-daily small-molecule GLP-1 receptor agonists, which puts them in direct competition. Orforglipron is significantly further along in development. Lilly’s phase 3 ATTAIN-1 trial readout in 2025 showed 14.7% mean weight reduction at 72 weeks on the highest dose. FDA approval is expected in 2026.

That timeline puts orforglipron in market a full three years ahead of AZD5004 at best. If orforglipron meets analyst forecasts and captures meaningful share of the oral GLP-1 segment, AstraZeneca will face a difficult path to differentiation by the time AZD5004 launches.

AstraZeneca has not disclosed structural details that would suggest AZD5004 has efficacy advantages. The bet appears to be on emerging differences in tolerability, pricing, or formulation rather than raw weight loss numbers.

What Is AZD6234?

AZD6234 is a long-acting amylin analog being developed for obesity. Amylin is a hormone co-secreted with insulin by pancreatic beta cells that produces satiety and slows gastric emptying. Pramlintide, an older amylin analog approved by the FDA in 2005, has limited use because of three-times-daily dosing requirements.

AZD6234 is engineered for once-weekly subcutaneous dosing. The molecule entered phase 2 trials for obesity in 2024 with topline data expected in late 2026.

Amylin is the same hormone class as cagrilintide, the amylin analog Novo Nordisk combined with semaglutide in CagriSema. The amylin mechanism appears to add weight loss benefit when stacked with GLP-1 receptor agonism, which means AstraZeneca could eventually combine AZD6234 with AZD5004 or another GLP-1 in a fixed-dose combination.

Does AstraZeneca Have Any Approved Obesity Drugs?

No. AstraZeneca’s current metabolic disease portfolio includes Farxiga (dapagliflozin), an SGLT2 inhibitor approved for type 2 diabetes, heart failure, and chronic kidney disease. Farxiga produces modest weight loss of roughly 2 to 3 kg in clinical trials, far below GLP-1 efficacy.

Bydureon (exenatide once-weekly) was an older GLP-1 marketed by AstraZeneca that the company divested in 2018 along with Symlin (pramlintide), Byetta, and other diabetes assets in a deal with VYV Therapeutics worth $200 million. AstraZeneca exited the GLP-1 space at exactly the wrong moment, just as semaglutide was beginning its rapid growth.

This history makes AstraZeneca’s late return to obesity drugs particularly notable. The company is essentially rebuilding a franchise it sold off six years before the market exploded.

What Did Pascal Soriot Say About the Obesity Strategy?

Pascal Soriot, AstraZeneca’s CEO, addressed the company’s obesity strategy in multiple investor presentations throughout 2024 and 2025. At the company’s November 2024 Capital Markets Day, Soriot said AstraZeneca planned to “build a meaningful obesity franchise” through a combination of oral therapies, amylin analogs, and combinations with the existing cardiometabolic portfolio.

Soriot has been candid about the timing problem. In a Q3 2024 earnings call he acknowledged that AstraZeneca “is not going to compete on speed with Lilly and Novo on the first wave” and described the company’s strategy as “second-generation differentiation” focused on convenience, tolerability, and cardiovascular benefit.

The company’s R&D guidance for 2026 includes increased spending on the obesity pipeline, particularly phase 3 readiness work for AZD5004 and earlier-stage combination programs.

How Does AstraZeneca’s Pipeline Compare to Competitors?

AstraZeneca trails the leaders by years on every major program. The current landscape:

Eli Lilly: tirzepatide on market in two indications, retatrutide (triple agonist) in phase 3, orforglipron (oral) likely to launch 2026, bimagrumab (muscle-sparing combo) in development.

Novo Nordisk: semaglutide on market across three brands, CagriSema phase 3 complete (missed primary endpoint), amycretin (amylin/GLP-1 dual) in phase 2 with strong early data.

Roche: acquired Carmot Therapeutics for $2.7 billion in December 2023, gaining CT-388 (GLP-1/GIP dual, similar mechanism to tirzepatide) and CT-996 (oral GLP-1). Phase 2 data on CT-388 showed 18.8% weight loss at 24 weeks in obese non-diabetic adults.

Pfizer: danuglipron development discontinued November 2023, now developing PF-07976016 once-daily oral GLP-1 in phase 2.

Amgen: MariTide (GLP-1/GIP receptor antagonist for monthly dosing) in phase 3.

AstraZeneca’s position is roughly comparable to Pfizer’s: a mid-stage organic pipeline with no near-term launches, dependent on differentiation that hasn’t yet been demonstrated in trials.

Key Takeaway: AstraZeneca acquired Amolyt Pharma in March 2024 and Icosavax in February 2024, but its obesity bets are largely organic

What About Combinations and Cardiovascular Benefits?

AstraZeneca’s existing strength in cardiovascular and renal disease creates one potential differentiation angle. The company markets Farxiga for heart failure and CKD and could combine SGLT2 inhibitors with GLP-1 receptor agonists or amylin analogs.

The clinical rationale exists. SGLT2 inhibition and GLP-1 receptor agonism both reduce cardiovascular mortality in trials but through different mechanisms. A fixed-dose combination could theoretically deliver more weight loss plus stronger cardiovascular benefit than either drug alone. No company has yet brought a GLP-1 plus SGLT2 inhibitor combination to phase 3.

AstraZeneca disclosed in 2024 that early-stage work on combinations with Farxiga and AZD5004 was underway, but no specific timeline has been published.

What Is AstraZeneca’s MASH Strategy?

Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) is the next major label expansion opportunity for GLP-1 drugs. Resmetirom (Madrigal’s Rezdiffra®) became the first FDA-approved MASH drug in March 2024 based on the MAESTRO-NASH trial published in NEJM in 2024. Semaglutide’s ESSENCE program reported positive interim results in late 2024. Tirzepatide’s SYNERGY-NASH phase 2 trial published in NEJM in June 2024 showed 62% MASH resolution at the 15mg dose.

AstraZeneca is developing a separate program with cotadutide, a GLP-1/glucagon dual agonist, specifically for MASH. Phase 2 data published in 2023 in The Lancet Gastroenterology and Hepatology showed cotadutide reduced liver fat by 39% at 19 weeks compared with placebo. The molecule has not yet entered phase 3.

A second program with AZD2693, an antisense oligonucleotide targeting PNPLA3, is in phase 2 for MASH in patients with the PNPLA3 I148M variant. This is a precision medicine approach distinct from the GLP-1 obesity strategy.

How Is AstraZeneca’s Obesity Strategy Reflected in Stock and Analyst Coverage?

Analyst sentiment on AstraZeneca’s obesity strategy is cautious. UBS analyst Trung Huynh wrote in a 2024 note that AstraZeneca’s pipeline “could generate $5 billion in peak obesity sales by 2032 in a successful scenario but more likely contributes $1-2 billion.” J.P. Morgan’s analyst team rates the obesity pipeline as “optionality” rather than a core driver of the AstraZeneca thesis.

The company’s stock has underperformed Eli Lilly significantly since 2022 in part because of the obesity franchise gap. AstraZeneca shares returned roughly 35% from January 2023 through January 2026 versus 220% for Eli Lilly over the same period.

That said, AstraZeneca’s broader oncology and rare disease portfolio drives most of its growth thesis. Obesity is not the centerpiece of the company’s strategy the way it is for Lilly and Novo.

What Does This Mean for Patients?

In the near term, nothing changes. AstraZeneca will not have an obesity drug on the market until 2028 to 2029 at the earliest. Patients seeking treatment in 2026 will continue to choose among semaglutide (Wegovy®, Ozempic®, compounded), tirzepatide (Zepbound®, Mounjaro®, compounded), and the few approved older drugs.

The longer-term outlook matters for pricing and competition. Each additional manufacturer entering with an approved obesity drug increases pricing pressure on the leaders. By 2030, the obesity market is expected to include products from at least four to six companies, which should drive better insurance coverage, more aggressive cash pricing, and broader patient access.

For patients seeking treatment today, the practical options remain branded GLP-1s through insurance or manufacturer direct programs, and compounded semaglutide or tirzepatide through licensed telehealth providers. TrimRx offers a free assessment quiz to determine eligibility for a personalized treatment plan.

Bottom line: Pascal Soriot publicly committed in 2024 to building “a meaningful obesity franchise” by 2030

FAQ

Does AstraZeneca Make a GLP-1 Drug?

Not yet. AstraZeneca divested its older GLP-1 portfolio (Bydureon, Byetta) in 2018 and is now rebuilding through AZD5004 (ECC5004), an oral once-daily small-molecule GLP-1 licensed from Eccogene in 2023. The drug is in phase 2 and the earliest realistic FDA approval is 2029.

What Is AZD5004?

AZD5004, also called ECC5004, is an oral once-daily small-molecule GLP-1 receptor agonist that AstraZeneca licensed from Chinese biotech Eccogene in November 2023. The deal is worth up to $1.825 billion in milestones. Phase 2 data is expected in 2026 with potential FDA approval in 2029 if trials succeed.

When Will AstraZeneca Launch a Weight Loss Drug?

The earliest realistic launch is 2028 to 2029, based on the current phase 2 stage of AZD5004 and AZD6234. Pascal Soriot has publicly committed to building a meaningful obesity franchise by 2030. The company is years behind Eli Lilly and Novo Nordisk on every major program.

What Is AZD6234?

AZD6234 is a long-acting once-weekly amylin analog in phase 2 trials for obesity. Amylin is the same hormone class as cagrilintide, the molecule Novo Nordisk combined with semaglutide in CagriSema. Topline phase 2 data is expected in late 2026.

How Does AstraZeneca Compare to Eli Lilly in Obesity?

AstraZeneca is years behind Eli Lilly on every major program. Lilly has Zepbound on the market generating $13.9 billion in 2025 sales, orforglipron likely to launch in 2026, and retatrutide in phase 3. AstraZeneca’s most advanced obesity candidate is still in phase 2.

Does AstraZeneca Have Any MASH Drugs?

Cotadutide, a GLP-1/glucagon dual agonist, is in development for MASH after phase 2 data showed a 39% liver fat reduction at 19 weeks. AZD2693, an antisense oligonucleotide for patients with the PNPLA3 I148M variant, is also in phase 2 for MASH.

Should I Wait for AstraZeneca’s Obesity Drug?

No. AstraZeneca’s earliest obesity drug launch is 2028 at the soonest. Patients who could benefit from GLP-1 therapy now have approved options including semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro), plus compounded options through telehealth platforms like TrimRx for those who don’t qualify for insurance coverage.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.

Related Articles

• Next-Generation GLP-1 Drugs: What’s in the Pipeline for 2026-2030
• GLP-1 Market Report 2026: Size, Growth & Key Players
• How AI Is Changing Drug Discovery for Obesity Medications
• GLP-1 and Health Insurance: Which Plans Cover What in 2026